Juan I. Luengo

3.1k total citations
58 papers, 1.5k citations indexed

About

Juan I. Luengo is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Juan I. Luengo has authored 58 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Molecular Biology, 27 papers in Organic Chemistry and 8 papers in Oncology. Recurrent topics in Juan I. Luengo's work include Bioactive Compounds and Antitumor Agents (6 papers), Biochemical and Molecular Research (6 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Juan I. Luengo is often cited by papers focused on Bioactive Compounds and Antitumor Agents (6 papers), Biochemical and Molecular Research (6 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Juan I. Luengo collaborates with scholars based in United States, United Kingdom and China. Juan I. Luengo's co-authors include Masato Koreeda, Dennis A. Holt, Kevin J. Duffy, John G. Gleason, Stephen G. Miller, Jon Rosen, Connie L. Erickson‐Miller, Evelyne Delorme, Hong Lin and Peter Lamb and has published in prestigious journals such as Science, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Juan I. Luengo

58 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Juan I. Luengo United States	23	731	476	341	215	122	58	1.5k
Alfred P. Spada United States	22	664 0.9×	789 1.7×	229 0.7×	172 0.8×	70 0.6×	44	1.8k
Juerg Zimmermann Switzerland	7	716 1.0×	581 1.2×	309 0.9×	356 1.7×	67 0.5×	10	1.6k
Hon‐Wah Man United States	17	784 1.1×	412 0.9×	459 1.3×	277 1.3×	247 2.0×	24	1.5k
Gabriele Fendrich Switzerland	18	943 1.3×	337 0.7×	543 1.6×	216 1.0×	84 0.7×	30	1.7k
Richard M. Keenan United States	23	576 0.8×	394 0.8×	167 0.5×	175 0.8×	70 0.6×	39	1.4k
Guido Bold Switzerland	25	907 1.2×	758 1.6×	131 0.4×	490 2.3×	74 0.6×	46	1.8k
Taekyu Lee United States	15	1.2k 1.6×	263 0.6×	218 0.6×	401 1.9×	133 1.1×	35	1.6k
Michael J. Munchhof United States	16	938 1.3×	413 0.9×	267 0.8×	340 1.6×	89 0.7×	30	1.6k
Michael Ohlmeyer United States	22	1.6k 2.2×	261 0.5×	241 0.7×	294 1.4×	156 1.3×	51	1.9k
Louis J. Lombardo United States	22	548 0.7×	567 1.2×	494 1.4×	252 1.2×	45 0.4×	54	1.7k

Countries citing papers authored by Juan I. Luengo

Since Specialization

Citations

This map shows the geographic impact of Juan I. Luengo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juan I. Luengo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juan I. Luengo more than expected).

Fields of papers citing papers by Juan I. Luengo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juan I. Luengo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juan I. Luengo. The network helps show where Juan I. Luengo may publish in the future.

Co-authorship network of co-authors of Juan I. Luengo

This figure shows the co-authorship network connecting the top 25 collaborators of Juan I. Luengo. A scholar is included among the top collaborators of Juan I. Luengo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juan I. Luengo. Juan I. Luengo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lee, Greg, et al.. (2024). Abstract LB163: Discovery and characterization of QTX3544, a potent, selective, and orally bioavailable allosteric G12V preferring multi KRAS inhibitor. Cancer Research. 84(7_Supplement). LB163–LB163. 2 indexed citations

Lee, Greg, et al.. (2023). Abstract LB320: Discovery and characterization of QTX3034, a potent, selective, and orally bioavailable allosteric KRAS inhibitor. Cancer Research. 83(8_Supplement). LB320–LB320. 7 indexed citations

Lee, Greg, et al.. (2023). Abstract LB321: Discovery and characterization of QTX3046, a potent, selective, and orally bioavailable non-covalent KRASG12D inhibitor. Cancer Research. 83(8_Supplement). LB321–LB321. 8 indexed citations

Lin, Honghuang & Juan I. Luengo. (2020). Exploiting binding-site arginines in drug design: Recent examples. Bioorganic & Medicinal Chemistry Letters. 30(19). 127442–127442. 4 indexed citations

Bhagwat, Neha, Yang Zhang, Hong Lin, et al.. (2020). Abstract 2915: Preclinical characterization of PRT543, a potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5), with broad antitumor activity in in vitro and in vivo models. Cancer Research. 80(16_Supplement). 2915–2915. 5 indexed citations

Lin, Hong, Karl F. Erhard, Mary Ann Hardwicke, et al.. (2012). Synthesis and structure–activity relationships of imidazo[1,2-a]pyrimidin-5(1H)-ones as a novel series of beta isoform selective phosphatidylinositol 3-kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 22(6). 2230–2234. 31 indexed citations

Vanderwall, Dana E., Nancy Yuen, James M. Bailey, et al.. (2011). Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery – the GSK experience. Drug Discovery Today. 16(15-16). 646–653. 8 indexed citations

Wang, Jizhou, Mark A. Seefeld, & Juan I. Luengo. (2011). Unusual ligand-dependent chemoselective Suzuki–Miyaura cross-coupling reactions of 3-bromo-4-trifloyl-thiophenes. Tetrahedron Letters. 52(48). 6346–6348. 14 indexed citations

Seefeld, Mark A., Meagan B. Rouse, Jizhou Wang, et al.. (2009). Discovery of 5-pyrrolopyridinyl-2-thiophenecarboxamides as potent AKT kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 19(8). 2244–2248. 21 indexed citations

10.

Erickson‐Miller, Connie L., Shin‐Shay Tian, Christopher B. Hopson, et al.. (2005). Species specificity and receptor domain interaction of a small molecule Tpo receptor agonist, SB-497115. Cancer Research. 65. 1163–1163. 2 indexed citations

11.

Erickson‐Miller, Connie L., Leslie Giampa, Christopher B. Hopson, et al.. (2004). Biological Activity and Selectivity for Tpo Receptor of the Orally Bioavailable, Small Molecule Tpo Receptor Agonist, SB-497115.. Blood. 104(11). 2912–2912. 27 indexed citations

12.

Jeong, Jae Uk, Xiaohong Chen, A. H. ABD EL RAHMAN, Dennis S. Yamashita, & Juan I. Luengo. (2004). An Efficient Synthesis of 3-Substituted 3H-Pyrimidin-4-ones. Organic Letters. 6(6). 1013–1016. 26 indexed citations

13.

Duffy, Kevin J., Anthony N. Shaw, Evelyne Delorme, et al.. (2002). Identification of a Pharmacophore for Thrombopoietic Activity of Small, Non-Peptidyl Molecules. 1. Discovery and Optimization of Salicylaldehyde Thiosemicarbazone Thrombopoietin Mimics. Journal of Medicinal Chemistry. 45(17). 3573–3575. 73 indexed citations

14.

Duffy, Kevin J., Alan T. Price, Evelyne Delorme, et al.. (2002). Identification of a Pharmacophore for Thrombopoietic Activity of Small, Non-Peptidyl Molecules. 2. Rational Design of Naphtho[1,2-d]imidazole Thrombopoietin Mimics. Journal of Medicinal Chemistry. 45(17). 3576–3578. 44 indexed citations

15.

Ohlstein, Eliot H., P Nambi, Douglas W.P. Hay, et al.. (1998). Nonpeptide Endothelin Receptor Antagonists. XI. Pharmacological Characterization of SB 234551, a High-Affinity and Selective Nonpeptide ETA Receptor Antagonist. Journal of Pharmacology and Experimental Therapeutics. 286(2). 650–656. 25 indexed citations

16.

Douglas, Stephen A., Ponnal Nambi, Miklos Gellai, et al.. (1998). Pharmacologic Characterization of the Novel, Orally Available Endothelin-A-Selective Antagonist SB 247083. Journal of Cardiovascular Pharmacology. 31. S273–S276. 5 indexed citations

17.

Willette, Robert N., Charles F. Sauermelch, Barbara L. Storer, et al.. (1998). Plasma- and Cerebrospinal Fluid-Immunoreactive Endothelin-1: Effects of Nonpeptide Endothelin Receptor Antagonists with Diverse Affinity Profiles for Endothelin-A and Endothelin-B Receptors. Journal of Cardiovascular Pharmacology. 31. S149–S157. 18 indexed citations

18.

Holt, Dennis A., Hye-Ja Oh, Leonard W. Rozamus, et al.. (1994). Structure-activity studies of synthetic FKBP ligands as peptidyl-prolyl isomerase inhibitors. Bioorganic & Medicinal Chemistry Letters. 4(2). 315–320. 28 indexed citations

19.

Luengo, Juan I. & Masato Koreeda. (1989). Complete control of the rearrangement modes of enolates of .alpha.-allyloxy ketones: reversal from the [3,3]-Claisen to the [2,3]-Wittig pathway by the use of the metalated N,N-dimethylhydrazones. The Journal of Organic Chemistry. 54(23). 5415–5417. 6 indexed citations

20.

Luengo, Juan I. & Masato Koreeda. (1984). Stereospecific synthesis of - and -1 alkoxy-1,3-butadienes. Tetrahedron Letters. 25(43). 4881–4884. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact